Therapeutic Asset Ratings

6,308 results matching 1 filter

91,583 assets · 7,906 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
cd3/cd19 negative allogeneic hematopoietic stem cells Common Variable Immunodeficiency	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells Chronic Obstructive Pulmonary Disease	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells Hyper-IgE Syndrome	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells Hyper-IgM Syndrome	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells T-Cell Immunodeficiency	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells Severe Congenital Neutropenia	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells Severe Combined Immunodeficiency	Paul Szabolcs	P1/2	CCC (48)
cd3/cd19 negative allogeneic hematopoietic stem cells Wiskott-Aldrich Syndrome	Paul Szabolcs	P1/2	CCC (48)
cd45ra depleted leukocytes Beta-Thalassemia Major	Paul Szabolcs	P1/2	CCC (48)
cd45ra depleted leukocytes Diamond-Blackfan Anemia	Paul Szabolcs	P1/2	CCC (48)
cd5-targeted car-t cells Precursor T-Cell Acute Lymphoblastic Leukemia	Peking University People's Hospital	P1/2	CCC (48)
cd7-cart01 T Lymphoblastic Leukemia/Lymphoma	Bambino Gesù Hospital and Research Institute	P1/2	CCC (48)
CDX 1140 Melanoma	University of Southern California	P1/2	CCC (48)
Cea-Targeted Car-T Malignant Pancreatic Neoplasm	Chongqing Precision Biotech Co., Ltd	P1/2	CCC (48)
Cea-Targeted Car-T Rectal Carcinoma	Chongqing Precision Biotech Co., Ltd	P1/2	CCC (48)
Celz-201-Ddt Lumbar Disk Degenerative Disorder	Creative Medical Technology Holdings Inc	P1/2	CCC (48)
CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) Acute Biphenotypic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (48)
CEPHALOTAXINE 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE (ESTER) Myelodysplastic Syndrome	M.D. Anderson Cancer Center	P1/2	CCC (48)
Cetuximab Skin Squamous Cell Carcinoma	Hummingbird Bioscience	P1/2	CCC (48)
Cetuximab Appendix Cancer	Allist Pharmaceuticals, Inc.	P1/2	CCC (48)
Cetuximab Diffuse Intrinsic Pontine Glioma	University of Miami	P1/2	CCC (48)
Cetuximab Fibrillary Astrocytoma	University of Miami	P1/2	CCC (48)
Cetuximab Diffuse Midline Glioma, H3 K27-Altered	University of Miami	P1/2	CCC (48)
Cetuximab Histiocytic And Dendritic Cell Neoplasm	Institut de Recherches Internationales Servier	P1/2	CCC (48)
Cetuximab Histiocytosis	Institut de Recherches Internationales Servier	P1/2	CCC (48)

Showing 976 to 1000 of 6,308 assets

PreviousPage 40 of 253Next